Mordena’s HIV Vaccine to Start Human Trials

Biotechnology company Mordena says it is preparing to begin human trials on HIV vaccines as early as Wednesday.

The company says it will be using the same mRNA platform, similar to the company’s Covid-19 vaccine.

The trials are set to start on 19 August and expected to be completed by spring 2023.

Mordena has two HIV vaccine candidates, mRNA-1644 and mRNA-1644v2-Core both of which have cleared initial safety testing before being used on humans for the first time.

Attempts to develop an HIV vaccine have been ongoing for decades but have met with little success. While multiple vaccine candidates have reached the trial stage, not all were found to be safe and almost none were shown to be even modestly effective.